title: [Non-immunological therapy in nephropathies leading to chronic renal failure and in post-transplant chronic renal dysfunction].
abstract: With its aging population, the Western world is experiencing a significant increase in the prevalence of chronic kidney disease, which has actually been defined as ''pandemic''. The high mortality and comorbidity, especially in terms of cardiovascular disease, have led to a significant increase in hospitalizations and rising public health expenditure, setting a trend that will become unsustainable in the next decades, even in the most developed countries. These epidemiological data have underlined the need for prevention campaigns and urged researchers and clinicians to develop new and more specific treatments able to slow down the progression of chronic kidney disease towards dialysis. To obtain such results, a deeper understanding of the pathogenetic mechanisms of nephropathy progression is mandatory. Once sclerosis is established and the initial pathogenetic noxa, whether or not involving the glomeruli, has been extinguished, the sclerotic progression of different nephropathies follows a standard pathway, irrespective of the initial cause. The achievement of an effective therapy for this condition, in native kidneys as well as transplanted organs, is the third-millennium challenge for nephrologists. In this review we will first describe the main risk factors and pathogenetic mechanisms involved in nephropathy progression and then discuss the results obtained with drugs that basic research has identified as potentially useful in experimental animal models as well as rigorous clinical trials.
authors.affiliation: S.C. Nefrologia Dialisi Trapianto, Policlinico Universitario Regina Margherita, Torino, Italy. alessandro.amore@unito.it
authors.forename: A
authors.initials: A
authors.lastname: Amore
authors.forename: R
authors.initials: R
authors.lastname: Camilla
authors.forename: C
authors.initials: C
authors.lastname: Rollino
authors.forename: E
authors.initials: E
authors.lastname: Avenatti
authors.forename: F
authors.initials: F
authors.lastname: Campolo
authors.forename: L
authors.initials: L
authors.lastname: Peruzzi
authors.forename: G
authors.initials: G
authors.lastname: Conti
authors.forename: R
authors.initials: R
authors.lastname: Coppo
mesh_terms: D002908:Chronic Disease; D002986:Clinical Trials as Topic; D018450:Disease Progression; D019317:Evidence-Based Medicine; D014943:Global Health; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007167:Immunotherapy; D007558:Italy / Q000453:epidemiology; D007674:Kidney Diseases / Q000503:physiopathology / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control / Q000628:therapy*; D007677:Kidney Function Tests; D007678:Kidney Glomerulus / Q000473:pathology; D016030:Kidney Transplantation; D015995:Prevalence; D006435:Renal Dialysis; D012307:Risk Factors; D012720:Severity of Illness Index